1Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：59
二级参考文献28
1Moses JW, Leon MB, Poprna JJ, et al. Sirolimus-eluting s-tents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003,349:1315-1323.
2Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-Ⅳ trial. Circulation. 2004;109:1942 - 1947.
3Moses JW. CYPHER trials. Presented at: American College of Cardiology Annual Scientific Session 2006 Rapid News Summaries; March 11-14, 2006; Atlanta, Ga. http://www.cardiosource.com /rapid newssu mmaries/index.asp?EID=22 &DoW=Mon&SumID=165. Accessed July 1, 2006.
4Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report fiom the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113:e85-e151.
5Leon MB, Bairn DS, Popma J J, et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenUng. N Engl J Med. 1998;339: 1665-1671.
6Cutlip DE, Balm DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001, 103:1967-1971.
7Berger PB, Mahaffey KW, Meier S J, et al. Safety and efficacy of only 2 weeks of ticlopicline therapy in patients at increased dsk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J. 2002;143:841-846.
8Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
9Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug- eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-2809.
10Regar E, Lemos PA, Saia F, et al. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am J Cardiol. 2004;93:1271- 1275.
3Vlaar PJ, Lennon R J, Rihal CS, et al. Drug-eluting stents in octogenarians : early and intermediate outcome[ J]. Am Heart J, 2008,155(4) :680 -682.
4Lagerqvist B, James SK, Stencstrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden [ J ]. N Engl J Med, 2007, 356(12) :1009 - 1019.
5Cura FA, Escudero AG, Berrocal D, et al. Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR) [ J ]. Am J Cardlol, 2007, 99 (3) :357 -363.
6Winchester D E, Wen X, Brarley W D, et al.Efficacy and safety of glycoprotein Ⅱb/Ⅲa iinhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines[J].J Am Coil Cardiol, 2011, 57(10): 1190-1199.
